Best of ASCO 2009
转载请注明来自丁香园
胡夕春
复旦大学附属肿瘤医院
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.
作者: 丁香园通讯员
| 以下网友留言只代表网友个人观点，不代表网站观点 | |||
Copyright 2000-2025 DXY.CN All Rights Reserved